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small molecules. The challenge, however, is in develop-
ing molecules with the specificity to selectively perturb
individual deacetylases. Will chemical biologists be able
to generate molecular probes of histone deacetylase
function that are both highly potent and specific in order
to harness the powerful suite of analytical tools available
to measure protein function at the global level? Can
chemical biologists not only ultimately dissect the func-
tion of the different deacetylase enzymes themselves
but also generate the tools to dissect the role of a given
deacetylase in different protein complexes (e.g., through
the generation of molecules that disrupt protein-proteinFigure 2. The Analysis of Genetic Perturbations Inherently Mea-
interactions)? Analogous to a saturating mutagenesissures the Steady-State Condition of a Cell and Hence Allows for
Indirect Effects for genetic screens, novel libraries of chemical diversity
Small-molecule perturbations, on the other hand, have the element directed against histone deacetylases will need to be
of temporal control and can thus, in principle, dissect biological generated and efficiently screened to further dissect
pathways with greater precision. histone deacetylase function.
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are now available in the form of enzyme-binding arrays,
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Recognizing a Something
When Your Library Sees It
In recent years those of us in the biomedical establish-
ment have been led to believe that more is better when
it comes to generating information and data. More data,Advances are needed in random-display technologies
well, that obviously means more drugs, right? But weto more tightly link drug actions and functions to the
learn early in life that a vast amount of information isgenes that control physiological processes. The re-
ports discussed here explore two sides of these is- only useful if you have a good referencing system by
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which you can pluck a signal from the noise. For in- for entirely in vitro-synthesized peptide and polypeptide
libraries, physically linked to their encoding nucleic acid.stance, in one virtual hand we hold the entire genome
sequences of many important organisms (even hu- The first such method, termed ribosome display, was
described by Mattheakis et al. [1] and was later improvedmans!). In the other hand, we either have existing drugs
that target specific proteins encoded by those genomes and simplified by Hanes and Plu¨cktun [2]. Roberts and
Szostak [3] brought yet another modification that would(human or pathogen), or we are seeking new drug candi-
dates to modulate the activity of defined or currently give rise to mRNA display. In mRNA display, mRNAs
encoding randomized peptides or full-length proteinsunidentified protein targets. Critically, having a drug in
hand is only half of the problem these days—if you are translated in vitro to yield mRNA-ribosome-peptide
complexes. Whereas in ribosome display these three-don’t know the target protein of a bioactive drug, then
optimization of drug activity for clinical purposes be- part complexes are stabilized and directly used in the
screen, in mRNA display the mRNA is covalently linkedcomes more onerous for the pharmaceutical chemist.
However, even if full knowledge of the target protein is to the peptide only, and this stable conjugate is then
used as the screening reagent. The current conjugationavailable, side effects that render drugs unusable are
often due to action upon additional unknown targets. method of choice is the addition of a puromycin moiety
to the 3 end of the mRNA by ligation of a DNA-puromy-Thus, the ability to characterize drug-target pairings can
be valuable for increasing both efficacy and specificity. cin linker. The ribosome initiates on the mRNA, synthe-
sizes the peptide, and stalls when it encounters the DNAOn the other side of the coin we have the issue of
creating drugs themselves. Phage display and other li- linker. This “pause” allows time for the puromycin to
enter the A site of the ribosome (and act as an amino-brary generation technologies have brought “screening”
approaches to the research masses. As the ease of acylated tRNA mimic) and covalently attach itself to the
carboxyl terminus of the peptide or polypeptide chain.generating drug-like candidates has increased, so has
the desire to elaborate upon the kinds of constituents In this way, the genetic material encoding the polypep-
tide is covalently attached to the corresponding poly-from which the libraries are made. What, then, is the
best path to (1) develop techniques to enable rapid cre- peptide product. Subsequently, if one can select for a
desired peptide function or activity, the correspondingation of novel libraries usable by the benchtop research
scientist and (2) give researchers a tool that allows mRNA comes along for the ride and can be character-
ized by PCR and other standard approaches. Tech-them to identify target proteins by defining a mode of
drug-target action? In this issue, McPherson et al. and niques are extant that allow libraries to reach complexi-
ties up to 1014 discrete polypeptide members with highMerryman et al. describe procedures that powerfully
address these two points. Merryman and colleagues affinity [4, 7].
In their report, Merryman et al. describe a novel ap-address the need to directly link gene to function by
using modified yeast tRNA, a method that is sufficiently proach by which one can attach the mRNA to the synthe-
sized peptide or polypeptide backbone. In this case,flexible to allow the use of novel chemical groups in
peptide side chains. McPherson and colleagues contrib- instead of using rabbit reticulocyte lysate, they used E.
coli extracts, which can be easily customized by addingute significantly to approaches that could speed up pro-
cesses by which drug companies might determine rele- or removing factors. This allowed the use of a novel
modified tRNAPhe (tRNAx), which is covalently linked tovant target proteins and avoid potentially disastrous
side effects. its amino acid Phenylalanine (Phe), by an amide group
that lies in place of the normal amino-acyl linkage. Con-Ribosome and mRNA display are common features
of the approaches described in these reports. These sequently, during translation, tRNAx becomes covalently
attached to the polypeptide and terminates elongationtechniques have proven to be of great utility in library
generation and library search stratagems over the years. of the nascent chain. In addition, the natural yeast
tRNAPhe contains a unique base, wybutine (Y base), thatAmong the first library-based strategies to gain wide-
spread attention were peptide libraries displayed on can be cross-linked to the mRNA near the anticodon by
UV treatment. The resultant amide-modified tRNAx isphage. Phage display libraries linked the genes carried
within the phage to a function—the binding of the pep- therefore a bifunctional reagent, enabling the polypep-
tide to be crosslinked to its corresponding mRNA, withtide displayed on the phage coat to some target moiety.
In addition, phage display libraries offered sufficient tRNAx acting as a bridge between the peptide and the
nucleic acid. When one mixes different ratios of theshape-space complexity to legitimatize investment in
their application. But, as we noted above, bigger is often tRNAx to tRNAPhe, each time the ribosome reads a Phe
codon the modified tRNAx has a certain chance of beingconsidered better, and thus in a quest for higher com-
plexities in shape-space, researchers have tried to in- incorporated at the ribosome A site and covalently at-
taching itself to the growing peptide. Subsequent UVcrease the sizes of the libraries to be screened. With in
vivo methods such as retroviral libraries or phage dis- treatment ensures attachment of the tRNAx-peptide to
the mRNA.play, the complexity is limited by the necessity of cellular
transformation after the ligation of the cDNA or peptide One caveat of using a modified tRNAPhe as a cross-
linking agent is that Phe codons are found throughoutinsert into the carrier vector. Transformation efficiencies
hardly ever gets better than 109. Certainly, library sizes mRNA sequences and also within the stretches of ran-
dom sequence that are an unavoidable result of libraryof as few as 106 peptides have shown great successes,
but for certain applications this may well be a limitation. production. Early incorporation of tRNAx rather than
tRNAPhe will result in shorter, incomplete peptides thatTo address this issue, in the last decade several re-
search teams have developed approaches that allow will be less likely to have a high affinity for a target
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structure. The functional diversity of such a library could play won’t do the trick because in vitro-translated pro-
be reduced. To solve this problem, the authors propose teins are devoid of such additions. However, one can
simultaneously lowering the effective concentration of take advantage of this weakness. In fact, one can select
the tRNAx and artificially increasing the representation for proteins bearing specific types of modifications,
of the Phe codon after the randomized region of the such as phosphorylation, as long as one can induce
mRNAs. Despite the fact that this could skew the library the modifications in vitro and specifically fish them out
toward a higher representation of members that encode afterwards. A good example of this is the recent paper
Phe at the C terminus, compromise should ensure that by Cujec et al., who used mRNA display to find targets
the library contains as few prematurely terminated mem- of the tyrosine kinase v-Abl by phosphorylating their
bers as possible. library with v-Abl and then isolating potential target
The authors prove the utility of this method as a means phosphorylated proteins [5].
of screening for small peptides that have a desired activ- The studies discussed in this preview, as well as oth-
ity by starting with a defined pool of mRNAs and generat- ers dealing with incorporation of nonnatural amino acids
ing an enriched subset encoding peptides that bind a [6], constitute important steps in demonstrating that we
specific matrix. The challenge for the authors is now to can fool the translation apparatus and harness its read-
attempt a real screen against an unknown target struc- ing/polymerizing capabilities to create highly complex
ture by using a larger, fully randomized library. If the libraries of not only peptides and proteins, but also poly-
authors can accomplish this (and the necessary scale- mers with potentially tailored pharmacological attri-
up for the creation of their tRNAx substrate), the tech- butes. Also, the fact that mRNA display is entirely done
nique could provide a valuable alternative to the puro- in vitro makes it more amenable to variation in the
mycin termination approach currently favored by the screening conditions. A bright future lies ahead for in
majority of researchers as a basis for variations on the vitro screening methods such as mRNA display, which
mRNA display theme. can be seen as complementing, or logically following,
After isolating a molecule or a peptide that has a in vivo, phenotypic screenings.
desirable phenotype in vivo, one is often faced with
the task of finding the cellular target of the compound.
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